Biocompatibility of an injectable in situ forming depot for peptide delivery

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4390-4399

  Schoenhammer, Karin ^a,b   Boisclair, Julie ^a   Schuetz, Helmut ^a   Petersen, Holger ^a   Goepferich, Achim ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Bioavailability; Biocompatibility; Biodegradable polymers; Controlled release delivery; Diffusion; Distribution; Excipients; Formulation; Hydrogels; In vitro in vivo correlation; Injectables; Peptide delivery; Peptides; Pharmakokinetics; Poly(lactic glycolic) acid (PLGA PLA); Polymer biodegradation; Polymeric drug carrier; Stability; Toxicology

Indexed keywords

MACROGOL DERIVATIVE; PASIREOTIDE; POLY(ETHYLENE GLYCOL) 500 DIMETHYLETHER; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; SUBCUTANEOUS TISSUE; SUSPENSION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION;

EID: 77957346507     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22149     Document Type: Article

References (27)

1. Rote Liste Service GmbH. 2008. Eligard 7.5 mg, Fachinformation.
2. U.S. Food and Drug Administration. 2003. Inactive Ingredient Search for Approved Drug Products.
3. Gad H, El-Nabarawi M, Abd El-Hady S. 2008. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis. AAPS PharmSciTech 9:878-884.
4. Middleton JC, Tipton AJ. 2000. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21:2335-2346.
5. Anderson JM, Shive MS. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-27.
6. Hasirci V, Lewandrowski K, Gresser JD, Wise DL, Trantolo DJ. 2001. Versatility of biodegradable biopolymers: Degradability and an in vivo application. J Biotechnol 86:135-150.
7. Daugherty AL, Cleland JL, Duenas EM, Mrsny RJ. 1997. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 44:89-102.
8. Singh S, Singh J. 2007. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: In vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 328:42-48.
9. Athanasiou KA, Agrawal CM, Barber FA, Burkhart SS. 1998. Orthopaedic applications for PLA-PGA biodegradable polymers. Arthroscopy 14:726-737.
10. Astaneh R, Erfan M, Moghimi H, Mobedi H. 2008. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci 98:135-145.
11. Kempe S, Metz H, Pereira PGC, Maeder K. 2010. Non invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur J Pharm Biopharm 74:55-66.
12. Royals MA, Fujita SM, Yewey Gerald L, Rodriguez J, Schultheiss PC, Dunn Richard L. 1999. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Res 45:231-239.
13. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. 2001. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 212:11-18.
14. Schoenhammer K, Petersen H, Guethlein F, Goepferich A. 2009. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability. Int J Pharm 371:33-39.
15. Schoenhammer K, Petersen H, Guethlein F, Goepferich A. 2009. Poly(ethyleneglycol) 500 dimethylether a novel solvent for injectable in situ forming depots. Pharm Res 26: 2568-2577.
16. Yeh KC, Small RD. 1989. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J Pharmacokinet Pharmacodyn 17:721-740.
17. Zolnik BS, Burgess DJ. 2008. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 127:137-145.
18. U.S. Food and Drug Administration. 1997. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms.
19. Burkersroda F. 2002. Dissertation: Untersuchung der homogenen und heterogenen erosion bioabbaubarer polymere.
20. Dunne M, Corrigan OI, Ramtoola Z. 2000. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21:1659-1668.
21. Gopferich A. 1997. Polymer bulk erosion. Macromolecules 30: 2598-2604.
22. Chen S, Singh J. 2008. Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation. Int J Pharm 352:58-65.
23. Kranz H, Yilmaz E, Brazeau G, Bodmeier R. 2008. In vitro and in vivo drug release from a novel in situ forming drug delivery system. Pharm Res 25:1347-1354.
24. Ravivarapu HB, Moyer KL, Dunn RL. 2000. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech 1: Article 1.
25. Martinez M, Rathbone M, Burgess D, Huynh M. 2008. In vitro and in vivo considerations associated with parenteral sustained release products: A review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 129:79-87.
26. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. 2002. Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res 19:1761-1768.
27. Burgess DJ, Crommelin DJA, Hussain AS, Chen ML. 2004. Assuring quality and performance of sustained and controlled release parenterals. Eur J Pharm Sci 21:679-690.